

Electronic Acknowledgement Receipt

EFS ID:	3386584
Application Number:	10572670
International Application Number:	
Confirmation Number:	4600
Title of Invention:	Polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline
First Named Inventor/Applicant Name:	Asa Elisabeth Gladwin
Customer Number:	20462
Filer:	Kathryn Lutomski Sieburth/Audrey Boyd
Filer Authorized By:	Kathryn Lutomski Sieburth
Attorney Docket Number:	PB60517
Receipt Date:	02-JUN-2008
Filing Date:	20-MAR-2006
Time Stamp:	10:55:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$300
RAM confirmation Number	6613
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part/.zip	Pages (if appl.)
1		ROA_2_13_08.pdf	806444 98e1749f5d3c5d95d1b4d0b3d3d3763 Signature471b1	yes	16

Multipart Description/PDF files in .zip description

Document Description	Start	End
Amendment - After Non-Final Rejection	1	1
Abstract	2	2
Specification	3	3
Claims	4	7
Applicant Arguments/Remarks Made in an Amendment	8	14
Drawings-only black and white line drawings	15	15
Abstract	16	16

Warnings:

Information:

2	Information Disclosure Statement Letter	IDS_w_Fee.pdf	63309 10e0effe0e70b60cbffec294cd1da92ce eef1675	no	2
---	---	---------------	---	----	---

Warnings:

Information:

3	Information Disclosure Statement (IDS) Filed	PTO_1449.pdf	112857 8dcaaff21379b9562d62197ce2ade63 e1b0371b	no	1
---	--	--------------	---	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

4	Foreign Reference	1WO2003035061A1.pdf	947044 545c3e6a749b52444776ab3e0db5fb5 0980322	no	32
---	-------------------	---------------------	--	----	----

Warnings:

Information:					
5	Foreign Reference	2WO2003066056A1.pdf	1031391 7a291afed83fb213363d8b25e9e8fc5 e689e9905	no	21
Warnings:					
Information:					
6	NPL Documents	3Woolley_Neuropharm_2001.pdf	258731 a3da374db2022aehb75ea016a75a 97cf78fa1	no	10
Warnings:					
Information:					
7	NPL Documents	4Mitchell_Pharmacol_Ther_2005.pdf	2006749 baf75a96da3e52239860207e4baa3e8 70f25711	no	14
Warnings:					
Information:					
8	NPL Documents	5Chuang_Alz_Dementia.pdf	594503 46dd44d01683511d3cf748e7ea3022 b683b6	no	5
Warnings:					
Information:					
9	NPL Documents	6London_SE_Announcement_2007.pdf	329366 dab94c043b9285abd0dc9d522978d78 8240329	no	4
Warnings:					
Information:					
10	NPL Documents	7Dose_Ranging_Study_SB742457_2007.pdf	131689 d80312d045bb9d0de103debc87590da 4b0b29690	no	4
Warnings:					
Information:					
11	NPL Documents	8SB742457_Donepezil_AD_2006.pdf	130389 25a690b567b9187a29ec1602c53267 8479c21b4	no	4
Warnings:					
Information:					
12	NPL Documents	9Garcia_Alloza_Neuropsychopharm_2004.pdf	1039342 e068783a9fb0f5d45134d47a74764f76c4f 74397ef	no	7
Warnings:					
Information:					
13	Fee Worksheet (PTO-06)	fee-info.pdf	8359 e3686ba3c3d8fecc4faa6e77994d5c feeinfo724	no	2
Warnings:					

Information:	Total Files Size (in bytes):	7460173
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>		
<p>New Applications Under 35 U.S.C. 111. If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>		
<p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>		
<p>New International Application Filed with the USPTO as a Receiving Office. If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>		